Global Preterm Birth and PROM Testing Market to Reach US$ 2.6 Billion by 2032, Stimulated by Advancements In Diagnostic Technologies

According to the latest report by IMARC Group, titled “Preterm Birth and PROM Testing Market Report by Test Type (Pelvic Exam, Ultrasound, Biochemical Markers, Uterine Monitoring, Nitrazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN), and Others), Application (PROM, Preterm Labor, Chorioamnionitis), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032,” the global preterm birth and PROM testing market size reached US$ 1.7 Billion in 2023. Preterm birth and premature rupture of membranes (PROM) testing are critical medical assessments that help identify and manage pregnancy-related complications. Preterm birth refers to the delivery of a baby 37 weeks before gestation, which can lead to various health issues for the infant. PROM occurs when the amniotic sac surrounding the fetus ruptures before the onset of labor. These conditions demand timely detection and intervention to ensure the best outcomes for the mother and baby. Preterm birth and PROM tests enable healthcare providers to assess a woman's risk of preterm birth or PROM, allowing for early intervention and preventive measures. They aid in confirming the diagnosis when symptoms like premature contractions or leaking amniotic fluid are present. It can guide medical professionals in making informed decisions about the timing and method of delivery to optimize the health of both mother and baby. Preterm birth and PROM testing are pivotal in reducing the risks associated with premature birth and enhancing the well-being of expectant mothers and their infants.

Global Preterm Birth and PROM Testing Market Trends:

The increasing awareness among healthcare providers and expectant mothers about the significance of early detection and proactive management of preterm birth risks are major factors contributing to the market growth. Moreover, rapid advancements in medical technology, such as precision diagnostics in the field of obstetrics and growing innovations in biomarker research, are positively impacting the market growth. In line with this, the development of non-invasive diagnostic tools empowering healthcare professionals with accurate and accessible means of assessing preterm birth and PROM risks is providing a considerable boost to the market growth. These technological advancements stream the testing process and improve diagnostic accuracy, ultimately favoring the market's growth. Additionally, the increasing prevalence of lifestyle-related risk factors, such as stress and poor nutrition, linking to an elevated risk of preterm birth and PROM and prompting a greater emphasis on early testing and preventive interventions, is providing a thrust to the market growth. Furthermore, the rising collaborations between healthcare institutions and pharmaceutical companies facilitating the development of novel diagnostic solutions are providing remunerative growth opportunities for the market. Looking forward, the market value is projected to reach US$ 2.6 Billion by 2032, expanding at a CAGR of 5% during 2024-2032.

Market Summary:

• Based on the test type, the market has been segmented into pelvic exam, ultrasound, biochemical markers [interleukin (IL)-6, C-reactive protein (CRP), IL-1, IL-2, IL-8, TNF-a, corticotropin-releasing hormone (CRH), and alpha-fetoprotein (AFP], uterine monitoring, nitrazine test, ferning test, pooling, PAMG-1 immunoassay, IGFBP test, fetal fibronectin (fFN), and others. According to the report, ultrasound represents the largest segment.
• On the basis of the application, the market has been divided into PROM, preterm labor, and chorioamnionitis. Among these, preterm labor represents the largest segment.
• Based on the end user, the market has been classified into hospitals, diagnostic laboratories, and others. According to the report, hospitals represent the largest segment.
• Region-wise, the market has been segmented into North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Among these, North America is the leading market, accounting for the majority of the global share.
• The competitive landscape of the market has also been examined, with some of the key players being Clinical Innovations LLC (Laborie Medical Technologies Inc.), Cooper Surgical Inc. (The Cooper Companies Inc.), Hologic Inc., IQ Products, NX Prenatal Inc., Qiagen N.V, Sera Prognostics, etc.

Report Coverage:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800